Dulaglutide
Metabolic Health, Weight Loss
In short
- An FDA-approved once-weekly GLP-1 receptor agonist (Trulicity), indicated for type 2 diabetes and cardiovascular risk reduction.
- Unlike semaglutide it is NOT approved for weight management — the weight effect is modest by comparison.
- Structurally distinct from the other GLP-1s here: it is an Fc-fusion protein, not a lipidated peptide.
- REWIND demonstrated cardiovascular benefit including in a primary-prevention population, which is unusual for the class.
- Weight loss is around 3-4 kg, meaningfully less than semaglutide or tirzepatide.
Structure
A GLP-1 analogue fused to a modified human IgG4 Fc fragment — a ~60 kDa recombinant protein. PubChem has no small-molecule entry, and proteins of this size are represented by sequence rather than a structure diagram.
How it works
Dulaglutide consists of two GLP-1 analogue molecules covalently linked to a modified human IgG4 Fc fragment. The Fc portion provides the long half-life — roughly five days — through neonatal Fc receptor recycling rather than the albumin binding that semaglutide and liraglutide use.
Its size prevents renal filtration, which is another contributor to persistence.
Receptor pharmacology is the same as the rest of the class: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite effects.
What the research shows
AWARD programme in type 2 diabetes: consistent HbA1c reductions, with superiority over several comparators.
REWIND: reduction in major adverse cardiovascular events over a median 5.4 years, notably in a population where the majority did NOT have established cardiovascular disease — making it one of the few primary-prevention results in the class.
Weight reduction is modest, around 3-4 kg, which is why it was never developed for obesity.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Human — type 2 diabetes, approved label | 0.75 mg weekly initially, increasing to 1.5, 3.0, or 4.5 mg weekly | subcutaneous | FDA label |
| Human — REWIND cardiovascular outcomes trial | 1.5 mg weekly | subcutaneous | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
No commonly reported ranges for this compound.
An approved medicine with a published label and a prefilled single-dose pen. Dosing should come from the label and the prescribing clinician.
Handling and storage
Supplied as a prefilled single-dose pen with the needle hidden — designed for ease of use. Once weekly, any day, with or without food, rotating injection sites.
No reconstitution and no dose measurement, which removes an entire category of error present with grey-market vials.
Side effects
Nausea, diarrhoea, vomiting, and abdominal pain dominate, dose-related and worst after escalation — the standard incretin profile.
Serious but uncommon: pancreatitis and gallbladder disease.
Boxed warning for thyroid C-cell tumours from rodent data; contraindicated with personal or family history of medullary thyroid carcinoma or MEN2.
As an Fc-fusion protein, immunogenicity is a theoretical consideration, though anti-drug antibodies have not been clinically significant in trials.
Combinations
Duplicating GLP-1 agonism with another incretin agent adds side effects without benefit.
With insulin or sulfonylureas, dose reduction of those agents is usually required to avoid hypoglycaemia.
Research status
The AWARD programme and REWIND together constitute a substantial, high-quality evidence base. This is properly evidenced medicine.
Legal status
FDA-approved and prescription-only in the US for type 2 diabetes and cardiovascular risk reduction, with equivalent status in the EU, UK, and elsewhere. Not approved for weight management anywhere.
WADA status
Not currently prohibited by WADA. Verify against the live list before competition.
Conclusion
Dulaglutide is a well-evidenced diabetes medicine with genuine cardiovascular outcome data, including in primary prevention — which is more than most of the class can claim.
It is also the weakest of the approved GLP-1s for weight loss, which is why almost nobody in this community uses it and why it was never developed for that purpose.
Sources
Track your own Dulaglutide protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.